ReviewMovement disorders : official journal of the Movement Disorder Society2022
How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?
Review in Movement disorders : official journal of the Movement Disorder Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- Olfactory changes in patients with Parkinson's disease undergoing deep brain stimulation in the subthalamic nucleus: a systematic review and meta-analysis.Neurosurgical review · 2025Pooled it
- Effect of deep brain stimulation on motor complications in Parkinson's disease: a systematic review and meta-analysis.Frontiers in human neuroscience · 2025Pooled it
- Effects of deep brain stimulation on functional autonomy and quality of life in Parkinson's disease: A systematic review and meta-analysis.Journal of Parkinson's disease · 2026Review
- Rethinking the concept of disease modification in an evolving Parkinson's disease treatment landscape.Journal of Parkinson's disease · 2026Review
- Article
- Refractory Motor Complications: Towards a Pragmatic Definition.Movement disorders clinical practice · 2026Article
- Genetically predicted CXCL16 expression is associated with Parkinson's disease risk and peripheral immune cell dysregulation: a two-sample mendelian randomization study.Molecular brain · 2026Article
- Morbidity, mortality, facility placement and cost of deep brain stimulation for Parkinson's disease.NPJ Parkinson's disease · 2026Article
- Brain Imaging Changes Following Deep Brain Stimulation Patients with Parkinson's Disease: A Literature Review.Movement disorders clinical practice · 2026Review
- Adaptive Deep Brain Stimulation for Parkinson's Disease: Navigating the Roadblocks to Clinical Implementation.Movement disorders : official journal of the Movement Disorder Society · 2026Review
- From continuous to adaptive deep brain stimulation: Personalized modulation improves motor complications and sleep in Parkinson's Disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Development and acceptability of a deep brain stimulation surgery decision aid for Parkinson's disease.Journal of Parkinson's disease · 2026Article
- Socio-Occupational Functioning after Subthalamic Deep Brain Stimulation in Parkinson's Disease.Movement disorders clinical practice · 2026Article
- Using explainable AI to identify disease-relevant and deep brain stimulation treatment-sensitive gait features in Parkinson's disease.Journal of neuroengineering and rehabilitation · 2026Article
- Survival after Subthalamic Deep Brain Stimulation for Parkinson's Disease: 25-Year Experience from a Single Center.Movement disorders clinical practice · 2026Article
- Advanced Therapeutics in Parkinson's Disease: What's New?Current neurology and neuroscience reports · 2026Review
- A modified Delphi study of post-operative management for subthalamic deep brain stimulation in Parkinson's disease.Journal of Parkinson's disease · 2026Article
- Denial of Hardware-Related Skin Erosion in Patients with Effective Deep Brain Stimulation: A Novel Phenomenon.Stereotactic and functional neurosurgery · 2026Article
- Long-Term Mortality and 10-Year Outcomes after Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease.Stereotactic and functional neurosurgery · 2026Article
- Propensity-matched multicenter comparison of Parkinson's disease outcomes with and without deep brain stimulation.NPJ Parkinson's disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A robust body of evidence from randomized controlled trials has established the efficacy of deep brain stimulation (DBS) in reducing off time and dyskinesias in levodopa-treated patients with Parkinson's disease (PD). These effects go along with improvements in on period motor function, activities of daily living, and quality of life. In addition, subthalamic DBS is effective in controlling drug-refractory PD tremor. Here, we review the available data from long-term observational and controlled follow-up studies in DBS-treated patients to re-examine the persistence of motor and quality of life benefits and evaluate the effects on disease progression, major disability milestones, and survival. Although there is consistent evidence from observational follow-up studies in DBS-treated patients over 5-10 years and beyond showing sustained improvement of motor control, the long-term impact of DBS on overall progression of disability in PD is less clear. Whether DBS reduces or delays the development of later motor and non-motor disability milestones in comparison to best medical management strategies is difficult to answer by uncontrolled observational follow-up, but there are signals from controlled long-term observational studies suggesting that subthalamic DBS may delay some of the late-stage disability milestones including psychosis, falls, and institutionalization, and also slightly prolongs survival compared with matched medically managed patients. These observations could be attributable to the sustained improvements in motor function and reduction in medication-induced side effects, whereas there is no clinical evidence of direct effects of DBS on the underlying disease progression. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.